Comparison of Medical RESCUE Strategies for Patients With Steroid-refractory Acute Severe Ulcerative Colitis: an Open-label Randomized Controlled Trial (RESCUE-UC).

Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 3
SUMMARY

This study aims to examine patients with acute severe UC who are refractory to intravenous corticosteroids and determine whether a strategy of using upadacitinib first followed by infliximab in upadacitinib non-responders is non-inferior to conventional management with infliximab only.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 64
Healthy Volunteers: f
View:

• Confirmed diagnosis of UC, based on conventional clinical, endoscopic, and/or histologic criteria

• Admitted to hospital with acute severe flare and refractory to three days of intravenous steroids (at minimum of 40mg methylprednisolone, or equivalent, daily). Refractory is defined using the Oxford criteria at day 3 of steroid therapy: presence of \> 8 stools/day or CRP \> 45 mg/L

• Will undergo or has already undergone a baseline colonoscopy or flexible sigmoidoscopy while in hospital or in the 4 weeks preceding trial entry, with a baseline MES ≥2 based on locally evaluated endoscopy

• Provided written informed consent

• Subject is willing and able to adhere to study procedures, and describe in the procedures that screening and safety monitoring procedures will be applied as per upadacitinib and infliximab Canadian product monographs

Locations
Other Locations
Canada
Hamilton Health Sciences
RECRUITING
Hamilton
Contact Information
Primary
Neeraj Narula
neeraj.narula@medportal.ca
905-521-2011
Time Frame
Start Date: 2025-04-16
Estimated Completion Date: 2027-09
Participants
Target number of participants: 134
Treatments
Active_comparator: Upadacitinib (treatment arm)
Participants will receive Upadacitinib 45mg daily, once a day, for at least five days.
No_intervention: Infliximab (standard care)
Participants will receive standard care, which is Infliximab.
Sponsors
Collaborators: AbbVie
Leads: McMaster University

This content was sourced from clinicaltrials.gov